Aeterna Zentaris recruits patients for ZoptEC Phase 3 study in ladies with advanced endometrial cancer Aeterna Zentaris Inc. today announced it has already reached its goal of recruiting 500 sufferers because of its pivotal Phase 3 ZoptEC clinical research with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer. The trial has been conducted in over 120 sites in North America, European countries and Israel. The primary efficacy endpoint is improvement in general survival. A second interim analysis is expected during Q4, 2015 at approximately 192 events, with the final analysis prepared at an anticipated 384 events.Table 1Table 1Baseline Characteristics and Primary Reason for Hospitalization in the Intention-to-Treat Population. Shows the baseline features of the sufferers.3 percent of the individuals were women. Over fifty % were hospitalized for severe systemic infection . The median duration of hospitalization was 9 times in both groups. The median duration of treatment was 6 days in both groups, with 93.9 percent of the patients receiving 6 to 2 weeks of treatment.